Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Multicentrická prospektivní kohorta srdeční sarkoidózy (CHASM-CS)

30. října 2026 aktualizováno: Ottawa Heart Institute Research Corporation

Multicentrická prospektivní kohortová studie srdeční sarkoidózy

Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.

There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.

A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.

Přehled studie

Postavení

Nábor

Podmínky

Detailní popis

Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).

Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.

Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.

All patients will be followed until the last patient recruited has been followed for 4 years.

The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.

There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.

The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.

Typ studie

Pozorovací

Zápis (Odhadovaný)

1500

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Janine E Ryan, BA(H), CCRP
  • Telefonní číslo: 17077 613-696-7000
  • E-mail: jryan@ottawaheart.ca

Studijní záloha kontaktů

Studijní místa

      • Sapporo, Japonsko, 060-8638
        • Nábor
        • Hokkaido University
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Ichizo Tsujino, MD
    • Alberta
      • Calgary, Alberta, Kanada, T2N 2T9
        • Nábor
        • Libin Cardiovascular Institute of Alberta
        • Vrchní vyšetřovatel:
          • Russell Quinn, MD
        • Kontakt:
          • Russell Quinn, MD
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Nábor
        • University of Alberta Hospital
        • Kontakt:
          • Tomascz Hruczkowski, MD
        • Vrchní vyšetřovatel:
          • Tomascz Hruczkowski, MD
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 1M9
        • Nábor
        • St. Paul's Hospital
        • Kontakt:
          • Shanta Chakrabarti, MD
        • Vrchní vyšetřovatel:
          • Shanta Chakrabarti, MD
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 3A7
        • Nábor
        • QEII Health Sciences Center
        • Vrchní vyšetřovatel:
          • Ciorsti MacIntyre, MD
        • Kontakt:
          • Kim Anderson, MD
    • Ontario
      • Hamilton, Ontario, Kanada, L8L 2X2
        • Nábor
        • Hamilton Health Sciences Centre
        • Vrchní vyšetřovatel:
          • Jeff Healey, MD
        • Kontakt:
          • Gerard Cox, MD
        • Kontakt:
          • Jeff Healey, MD
      • London, Ontario, Kanada, N6A 5A5
        • Nábor
        • London Health Sciences Centre
        • Kontakt:
          • Lorne Gula, MD
        • Vrchní vyšetřovatel:
          • Lorne Gula, MD
      • Newmarket, Ontario, Kanada, L3Y 2P9
        • Nábor
        • Southlake Regional Health Centre
        • Kontakt:
          • Bernice Tsang, MD
        • Vrchní vyšetřovatel:
          • Bernice Tsang, MD
      • Ottawa, Ontario, Kanada, K1Y 4W7
        • Nábor
        • University of Ottawa Heart Institute
        • Kontakt:
        • Vrchní vyšetřovatel:
          • David Birnie, MD
        • Kontakt:
      • Toronto, Ontario, Kanada, M5G 2C4
        • Nábor
        • Toronto General Hospital
        • Kontakt:
          • Andrew Ha, MD
        • Vrchní vyšetřovatel:
          • Andrew Ha, MD
    • Quebec
      • Montreal, Quebec, Kanada, H1T 1C8
        • Nábor
        • Montreal Heart Institute
        • Kontakt:
          • Lena Rivard, MD
        • Vrchní vyšetřovatel:
          • Lena Rivard, MD
      • Montreal, Quebec, Kanada, H3G 1A4
        • Nábor
        • McGill University Health Centre
        • Kontakt:
          • Fiorella Rafti
        • Vrchní vyšetřovatel:
          • Martin L Bernier, MD
      • Montreal, Quebec, Kanada, H2W 1T8
        • Zatím nenabíráme
        • Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
        • Kontakt:
          • Julie Fleury, RN
        • Vrchní vyšetřovatel:
          • Benoit Coutu, MD
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4P 0W5
        • Nábor
        • Prairie Vascular Research Inc-Regina General Hospital
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Andrea Lavoie, MD

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 99 let (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Ukázka pravděpodobnosti

Studijní populace

Electrophysiology Service patients

Popis

Inclusion Criteria:

To diagnose Clinically Manifest CS all following criteria must be met:

(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS

To diagnose clinically silent CS all of the following criteria must be met

(i) Biopsy proven extra-cardiac sarcoidosis

AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis

AND (iii) CMR suggestive of cardiac sarcoidosis

AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)

Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control

Exclusion Criteria:

  • unable or unwilling to provide informed consent
  • patients who are pregnant or lactating
  • patients with known claustrophobia
  • age < 18 years

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
CS screened as underlying etiology
  1. Patients with active Clinically Manifest CS
  2. Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Primary Outcome for ALL Patients
Časové okno: Through study completion, on average 10 years

The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation.

Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure.

Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Secondary Outcomes for ALL Patients
Časové okno: Through study completion, on average 10 years

1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for ALL Patients
Časové okno: Through study completion, on average 10 years

2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Časové okno: Through study completion, on average 10 years

1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Časové okno: Through study completion, on average 10 years

2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Časové okno: Through study completion, on average 10 years

3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Časové okno: Through study completion, on average 10 years

4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Časové okno: Through study completion, on average 10 years

5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Časové okno: Through study completion, on average 10 years

6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Časové okno: Through study completion, on average 10 years

7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
Časové okno: Through study completion, on average 10 years

8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
Časové okno: Through study completion, on average 10 years

1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Pablo Nery, MD, Ottawa Heart Institute Research Corporation
  • Vrchní vyšetřovatel: Rob Beanlands, MD, Ottawa Heart Institute Research Corporation
  • Vrchní vyšetřovatel: David Birnie, MD, Ottawa Heart Institute Research Corporation

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

1. srpna 2012

Primární dokončení (Odhadovaný)

1. března 2027

Dokončení studie (Odhadovaný)

1. prosince 2035

Termíny zápisu do studia

První předloženo

10. listopadu 2011

První předloženo, které splnilo kritéria kontroly kvality

18. listopadu 2011

První zveřejněno (Odhadovaný)

22. listopadu 2011

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

4. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

30. října 2026

Naposledy ověřeno

1. června 2026

Více informací

Termíny související s touto studií

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit